This study focuses on patients with advanced ALK-positive non-small cell lung cancer, a specific type of lung cancer that has a particular genetic change. The research examines two treatment approaches: a combination therapy using multiple medications and a single medication treatment. The medications being studied include brigatinib (taken as tablets by mouth), carboplatin (given through a vein), and pemetrexed (given through a vein).

The main purpose of this research is to evaluate how well the combination of these medications works in treating this type of lung cancer. The study will track how patients respond to treatment over time, including how the cancer responds and what side effects may occur. Some patients will receive brigatinib alone, while others will receive brigatinib together with carboplatin and pemetrexed.

During the study, patients will receive regular medical check-ups and undergo various tests to monitor their health and how well the treatment is working. The treatment period may last up to 60 months, with regular assessments of the cancer’s response to treatment. The medications will be given in specific doses, with brigatinib taken daily as tablets, while carboplatin and pemetrexed will be given through an intravenous line at scheduled intervals.